Introduction to FDA Review and Approval of Biological Products
Review the statutory definitions of a biological product as well as distinctions that drive jurisdiction and regulatory pathway. Discuss pathways to market and how to determine which pathway to choose. Review of the Biologics Price Competition and Innovation Act of 2009 (BPCIA). Examine market exclusivities and intellectual property.
Catherine M. Cook, Executive Vice President, Drugs & Biological Products, Greenleaf Health, Inc.
This session was recorded as part of FDLI’s Virtual Introduction to Biologics and Biosimilars Laws and Regulations Course in March/April 2020.
- +$100 for nonmembers
Virtual Learning FAQ
On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.
On-demand content can be played back on most devices.
If you have concerns, please click the Test Your System link to determine your device’s compatibility, as well as system requirements.
CLE credit is not currently available for pre-recorded sessions.